Mizuho analyst Christopher Parkinson maintains Celanese (NYSE:CE) with a Neutral and lowers the price target from $108 to $107.
HC Wainwright & Co. Initiates Coverage On LAVA Therapeutics with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Arthur He initiates coverage on LAVA Therapeutics (NASDAQ:LVTX) with a Buy rating and announces Price Target of $9.